Breaking Now



Cyprotex PLC
11 November 2003



Press Release 11 November 2003



Cyprotex reports successful customer validation studies for CloeTM Technology



Cyprotex (LSE: CRX) today announces results of successful trials of its Cloe PK
TM software applied to over 150 potential drugs provided by seven pharmaceutical
companies. The trials showed that Cloe PKTM can estimate how long a drug stays
in the body and is sufficiently accurate to be used in the rapid selection of
promising compounds and the early elimination of those likely to fail.



In parallel, blind trials of the Cloe ScreenTM experimental testing technology
on several hundred compounds provided by six laboratories from major
pharmaceutical companies, all demonstrated a high degree of accuracy.



The CloeTM technology can be used to predict what would happen in humans as well
as in rats, one of the main species used in pharmaceutical research, and the
cumulated data showed that the CloeTM technology allowed the estimation of human
outcomes more accurately than experiments carried out in live rats. These
results demonstrate that customers can confidently use the CloeTM technology to
reduce the number of animals they use in drug discovery research, while
improving the chance that their drug would work in humans.



The detailed results of the trials were described to leading industry and
academic practitioners in the field of computer-based prediction for drug
discovery, who recently visited Cyprotex's laboratories in Macclesfield. The
event was a satellite meeting of the UK QSAR (see below) Discussion Group
meeting, a twice-yearly event which allows industry and academic scientists to
exchange information on progress in the development of computer-based predictive
approaches, which was also hosted by Cyprotex.



Dr David Leahy, Chief Scientific Officer and Founder of Cyprotex plc, said: 'I
am proud of the way that our skilled team of scientists and engineers have
delivered, in less than 18 months, uniquely accurate and cost-effective
technology for the estimation of pharmacokinetics.



'We now have the evidence that demonstrates to potential partners that the Cloe
TM technology can improve productivity in drug discovery. We are able to offer
to our partners similar information to that obtained in a Phase One clinical
trial on every compound they synthesise, at a fraction of the cost, within days
rather than years.'



The acronym QSAR stands for Quantitative Structure-Activity Relationships and
refers to mathematical or statistical relationships between the chemical
structure of a drug and its properties.

- Ends -



Media enquiries:
Bankside
Henry Harrison-Topham / Heather Salmond Tel: +44 (0) 20 7444 4140
heather.salmond@bankside.com www.bankside.com


Notes to editors:

Cyprotex PLC

Cyprotex is a specialist provider of pharmacokinetic information and technology
to evaluate and optimise key properties of potential drugs that determine how
well they will be absorbed, distributed, metabolised and excreted by the body.
This provides pharmaceutical partners with a sound basis for decision-making
regarding compound selection and design that takes into account how the compound
will behave in the body. Cyprotex predicts the likely outcome of administering
either orally or intravenously administered compounds by modelling human and rat
physiology. Predictions require basic compound information that can be derived
in the laboratory using established methods, all of which are routinely
performed by Cyprotex's experimental capability. This unique combination of
technologies is aimed at improving pharmaceutical productivity by improving the
quality of compound libraries and drug candidates progressing through the drug
pipeline. Cyprotex is based in the UK and is listed on the Alternative
Investment Market of the London Stock Exchange (CRX).


This information is provided by RNS
The company news service from the London Stock Exchange

Great news & the orders should start to flood in!

IMHO this AGM statement is truly showing the city and investors that the past is in the past with issues of 'The Plumber' and Sheffield University now dead and burried. Cyprotex is clearly showing confidence that Cloe Screen & Cloe PK are excellent products/services and are increasing in demand by the major pharmaceuticals.

Read on :-

Cyprotex PLC
03 June 2004






Press Release 3 June 2004



Cyprotex Plc
('Cyprotex' or 'the Company')

AGM Statement



Cyprotex (LSE: CRX) announces today that, at the Company's Annual General
Meeting, held earlier today, all resolutions before the meeting were duly
passed.



Speaking at the meeting in Swindon, Robert Morrisson Atwater, Chairman and CEO
of Cyprotex plc, said: 'Cyprotex has continued its excellent progress in the
current financial year to date. Central to our progress during this period has
been our continued delivery on contracts won in the current financial year with
a number of well-known pharmaceutical companies. These customers have reported
positive feedback on the Cyprotex product mix not only to us but also to the
industry as a whole leading to a number of new business contracts. As a result,
we are positive that we are on track to achieve 1.9 million of sales by the end
of this financial year and for the Company to continue in its sustained growth.'



- Ends -

For further information:
Cyprotex PLC
Robert Morrisson Atwater, Tel: +44 (0) 1625 505 152

Chairman & Chief Executive Officer
ir@cyprotex.com www.cyprotex.com


Media enquiries:
Bankside
Henry Harrison-Topham / Heather Salmond Tel: +44 (0) 20 7444 4140
henry.ht@bankside.com www.bankside.com


Notes to editors:



Cyprotex PLC - www.cyprotex.com
Cyprotex is a specialist provider of pharmacokinetic information and technology
to evaluate and optimise key properties of potential drugs that determine how
well they will be absorbed, distributed, metabolised and excreted by the body.
This provides pharmaceutical partners with a sound basis for decision-making
regarding compound selection and design that takes into account how the compound
will behave in the body. Cyprotex predicts the likely outcome of administering
either orally or intravenously-administered compounds by modelling human and rat
physiology. Predictions require basic compound information that can be derived
in the laboratory using established methods, all of which are routinely
performed by Cyprotex's experimental capability. This unique combination of
technologies is aimed at improving pharmaceutical productivity by improving the
quality of compound libraries and drug candidates progressing through the drug
pipeline. Cyprotex is based in the UK and is listed on the London Stock
Exchange (CRX).


This information is provided by RNS
The company news service from the London Stock Exchange


This certainly restores my faith as a shareholder that this company is a good long term investment. The share has fallen from 25p in Jan04 to 11.5p and is now very cheap as currently it is at the price it was last Jun03 despite the facts there has been consistent positive news stream coming out of CRX and provisions for exceptionals items (Sheffield Univertsity) had already been made in it's accounts over a year ago!

From a charting and short term TA viewpoint the MACD has generated a buy signal 3 trading days ago and the RSI also generated a strong buy signal as it crossed sharply above it's 10day moving average which lends to indicate MM's are Bullish with a marketable company share to sell to investors.

The AGM statement should do the trick and the share price could easily surge back up to 25p by the time next Interims are expected out on or around 30 Sept, particularly as the statement also indicates several further contract news is fairly imminent.

DYOR and post your comments but IMHO a very positive share to now BUY and will be buying some more to add to my holding.

fully agree with poster and expect with all the news ref agreements etc,the value of these agreements will be in next interims,believe only one way to go and that is up.

Since I last posted on this thread it seems Cyprotex are certainly begining to be making headway.

1st Jul 04 Cyprotex and Peakdale Collaborate in ADME Prediction Technology for More Efficient Drug Discovery

9th Aug 04 Artemis Investment Management Limited holds 7,250,000 shares

20th Sep 04 Interim Report and Accounts for the six months ended 30 June 2004 These are the highlights and worth reading further.

Turnover up by 140% at 886,000 (369,000)
Gross profit 185% higher at 734,000 (257,000)
Pre-tax loss over 22% lower at 832,000 (1.08 million)
Placing of 2.94 million (net of expenses) at beginning of period leaves cash balances at 2.7 million (868,000)
Customer portfolio expanded to 25 major companies including revenue generating contracts with Roche, AstraZeneca, Altana and Solvay
Contractual discussions well advanced with further blue-chip pharmaceutical and biotechnology companies.

8th Oct 04 Serono integrates Cloe Screen and Cloe PK into its drug discovery strategy

12th Oct 04 Director Shareholding

12th Dec 04 Director Shareholding

21st Dec 04 Director Shareholding

And the chart for CRX is now confirming this by showing a rising trend.